UNSPSC 51334311: Clopenthixol dihydrochloride

This classification denotes a dopamine antagonist with the molecular formula C22H26Cl2N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R3BMY435Z0, chemically known as 1-piperazineethanol, 4-(3-(2-chloro-9h-thioxanthen-9-ylidene)propyl)-, hydrochloride (1:2), but more generally known as clopenthixol dihydrochloride, which bears US NIH Compound Identifier 5372683. European Medicines Agency schedules clopenthixol dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06736MIG.

Most nations, for tariff purposes, schedule clopenthixol dihydrochloride under HS 29349990. SMILES:.

UNSPSC 51334311 Clopenthixol dihydrochloride is a Commodity code that reflects state and local procurement of pharmaceutical active pharmaceutical ingredients and finished drugs, though recent solicitation activity shows substantial misalignment between the nominal code scope and what jurisdictions are actually buying. The three recent opportunities tagged to this code cover naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer pharmacy benefit programs (Texas HHS Commission), and generic multi-source pharmaceuticals distributed through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon). The actual work consists of supply agreements for finished pharmaceutical products, OTC medications, and related health-system consumables procured by county health departments, state health agencies, and multi-state cooperative purchasing vehicles. Issuing bodies span counties (Seminole County), state health agencies (Texas HHS Commission), and state procurement offices administering cooperative purchasing agreements (Minnesota Department of Administration). The code shows little targeted activity for clopenthixol dihydrochloride specifically—the opportunities appear to reflect misclassification or broad tagging of pharmaceutical procurement across multiple product lines.

Recent solicitations span Florida, Texas, and Minnesota with a multi-state cooperative purchasing dimension through MMCAP. Seminole County issued an IFB (Solicitation IFB60459723LAS, response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, requiring electronic bid submission and E-Verify compliance with a fixed two-year term and optional one-year renewal. Texas HHS Commission issued an RFI (HHS0017013, posted April 3, 2026) seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's Office of State Procurement administered an RFP through MMCAP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products with distribution through three authorized wholesalers, effective July 1, 2026, with weighted evaluation favoring price competitiveness at 75 percent and requiring current Good Manufacturing Practices and Drug Supply Chain Security Act compliance. Given the code-to-opportunity mismatch, activity under the specific clopenthixol dihydrochloride commodity is not evident; the tagging reflects broader pharmaceutical procurement rather than sourcing of this particular active ingredient.